Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells

Journal of Biological Chemistry

Volumn 287, Issue 6, 2012, Pages 3777-3787

  Soifer, Harris S ^a   Souleimanian, Naira ^a   Wu, Sijian ^a   Voskresenskiy, Anatoliy M ^a   Collak, Filiz Kisaayak ^b   Cinar, Bekir ^b   Stein, Cy A ^a  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTORS; MOLECULAR MECHANISM; MRNA EXPRESSION; PROSTATE CANCER CELLS; PROSTATE CELLS; PROTEIN EXPRESSIONS; RADIOLIGANDS; RATE-LIMITING ENZYMES; TRANSCRIPTIONAL ACTIVITY; WILD TYPES;

BIOCHEMISTRY; CELLS; PROTEINS; UROLOGY;

DISEASES;

ABIRATERONE; ANDROGEN RECEPTOR; CYTOCHROME P450 17; GALETERONE; INITIATION FACTOR 4E BINDING PROTEIN 1; INITIATION FACTOR 4F; INITIATION FACTOR 4G; METRIBOLONE;

ARTICLE; BINDING COMPETITION; CANCER CELL; CELL NUCLEUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; RNA CAPPING; TRANSACTIVATION; TRANSCRIPTION REGULATION; TRANSLATION REGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID SUBSTITUTION; ANDROSTADIENES; ANDROSTENOLS; BENZIMIDAZOLES; CELL LINE, TUMOR; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MUTATION, MISSENSE; PHOSPHOPROTEINS; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANDROGEN; STEROID 17-ALPHA-HYDROXYLASE;

EID: 84863011652     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M111.261933     Document Type: Article

References (59)

1. Thomson, A. A. (2001) Role of androgens and fibroblast growth factors in prostatic development. Reproduction 121, 187-195
2. Yong, E. L., Lim, J., Qi, W., Ong, V., and Mifsud, A. (2000) Molecular basis of androgen receptor diseases. Ann. Med. 32, 15-22 (Pubitemid 30103427)
3. Masiello, D., Cheng, S., Bubley, G. J., Lu, M. L., and Balk, S. (2002) Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J. Biol. Chem. 277, 26321-26326 (Pubitemid 34967123)
4. Farla, P., Hersmus, R., Trapman, J., and Houtsmuller, A. (2005) Antiandrogens prevent stable DNA binding of the androgen receptor. J. Cell Sci. 118, 4187-4198 (Pubitemid 41488956)
5. Singh, P., Uzgare, A., Litvinov, I., Denmeade, S., and Isaacs, J. (2006) Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr. Related Cancer 13, 653-666 (Pubitemid 44763250)
6. Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., and Sawyers, C. L. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33-39 (Pubitemid 38524696)
7. Snoek, R., Cheng, H., Margiotti, K., Wafa, L. A., Wong, C. A., Wong, E. C., Fazli, L., Nelson, C. C., Gleave, M. E., and Rennie, P. S. (2009) In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin. Cancer Res. 15, 39-47
8. Mostaghel, E., Montgomery, R., and Lin, D. (2007) The Basic Biochemistry and Molecular Events of Hormone Therapy. Curr. Urol. Rep. 8, 224-232 (Pubitemid 46806652)
9. Mohler, J. L., Gregory, C. W., Ford, O. H., 3rd, Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., and French, F. S. (2004) The androgen axis in recurrent prostate cancer. Clin. Cancer Res. 10, 440-448 (Pubitemid 38173980)
10. Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotìe, A., Tammela, T., Isola, J., and Kallioniemi, O. P. (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9, 401-406
11. Koivisto, P., Kononen, J., Palmberg, C., Tammela, T., Hyytinen, E., Isola, J., Trapman, J., Cleutjens, K., Noordzij, A., Visakorpi, T., and Kallioniemi, O. P. (1997) Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 57, 314-319 (Pubitemid 27036612)
12. Taplin, M. E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., and Balk, S. P. (1995) Mutation of the androgenreceptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332, 1393-1398
13. Tilley, W. D., Buchanan, G., Hickey, T. E., and Bentel, J. M. (1996) Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin. Cancer Res. 2, 277-285 (Pubitemid 26074615)
14. Lin, H. K., Altuwaijri, S., Lin, W. J., Kan, P. Y., Collins, L. L., and Chang, C. (2002) Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. J. Biol. Chem. 277, 36570-36576
15. Geller, J., Albert, J., Loza, D., Geller, S., Stoeltzing, W., and de la Vega D. (1978) DHT concentrations in human prostate cancer tissue. J. Clin. Endocrinol. Metab. 46, 440-444 (Pubitemid 8305058)
16. Geller, J., Albert, J., and Loza, D. (1979) Steroid levels in cancer of the prostate-markers of tumour differentiation and adequacy of anti-androgen therapy. J. Steroid Biochem. 11, 631-636 (Pubitemid 9245942)
17. Huang, Z. Q., Li, J., and Wong, J. (2002) AR possesses an intrinsic hormone- independent transcriptional activity. Mol. Endocrinol. 16, 924-937 (Pubitemid 34478531)
18. Zegarra-Moro, O. L., Schmidt, L. J., Huang, H., and Tindall, D. J. (2002) Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res. 62, 1008-1013 (Pubitemid 34160279)
19. Li, T. H., Zhao, H., Peng, Y., Beliakoff, J., Brooks, J. D., and Sun, Z. (2007) A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells. Nucleic Acids Res. 35, 2767-2776 (Pubitemid 47073687)
20. Balk, S. (2002) Androgen receptor as a target in androgen-independent prostate cancer. Urology 60, 132-138
21. Balk, S., and Knudsen, K. (2008) AR, the cell cycle, and prostate cancer. Nucl. Recep. Signal 6, e001
22. Xing, N., Chen, Y., Mitchell, S., and Young, C. (2001) Quercetin inhibits the expression and function of the androgen receptor In LNCaP prostate cancer cells. Carcinogenesis 22, 401-414
23. Zhu, W., Smith, A., and Young, C. Y. (1999) A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells. Endocrinology 140, 5451-5454
24. Mitchell, S. H., Zhu, W., and Young, C. Y. (1999) Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res. 59, 5892-5895 (Pubitemid 30004946)
25. Chiu, F. L., and Lin, J. K. (2008) Down-regulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts. Prostate 68, 61-71
26. Kuroda, K., Liu, H., Kim, S., Guo, M., Navarro, V., and Bander, N. (2009) Docetaxel down-regulates the expression of androgen receptor and prostate- specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: Implications for PSA surrogacy. Prostate 69, 1579-1585
27. Lin, F. M., Chen, L. R., Lin, E. H., Ke, F. C., Chen, H. Y., Tsai, M. J., and Hsiao, P. W. (2007) Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells. Carcinogenesis 28, 2521-2529
28. Liao, X., Tang, S., Thrasher, J. B., Gribling, T., and Li, B. (2005) Smallinterfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol. Cancer Therap. 4, 505-515 (Pubitemid 40601831)
29. Ko, Y. J., Devi, G. R., London, C. A., Kayas, A., Reddy, M. T., Iversen, P. L., Bubley, G. J., and Balk, S. P. (2004) Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers. J. Urol. 172, 1140-1144 (Pubitemid 39096488)
30. Eder, I. E., Culig, Z., Ramoner, R., Thurnher, M., Putz, T., Nessler-Menardi, C., Tiefenthaler, M., Bartsch, G., and Klocker, H. (2000) Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Therap. 7, 997-1007 (Pubitemid 30483479)
31. Koch, T., and Oerum. H. (2008) in Antisense Drug Technology, 2 Ed. (Crooke, S., ed), pp. 519-562, CRC Press, Boca Raton, FL
32. Ferrari, N., Bergeron, D., Tedeschi, A. L., Mangos, M. M., Paquet, L., Renzi, P. M., and Damha, M. J. (2006) Characterization of antisense oligonucleotides comprising 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (FANA): specificity, potency, and duration of activity. Ann. N.Y. Acad. Sci. 1082, 91-102 (Pubitemid 44955454)
33. Stein, C. A., Hansen, J. B., Lai, J., Wu, S., Voskresenskiy, A., Høg, A., Worm, J., Hedtjärn, M., Souleimanian, N., Miller, P., Soifer, H. S., Castanotto, D., Benimetskaya, L., Ørum, H., and Koch, T. (2010) Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res. 38, e3
34. Handratta, V. D., Vasaitis, T. S., Njar, V. C., Gediya, L. K., Kataria, R., Chopra, P., Newman, D., Jr., Farquhar, R., Guo, Z., Qiu, Y., and Brodie, A. M. (2005) Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J. Med. Chem. 48, 2972-2984 (Pubitemid 40552912)
35. Attard, G., Reid, A. H., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., Clark, J., Cooper, C. S., Kaye, S. B., Dearnaley, D., Lee, G., and de Bono, J. S. (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26, 4563-4571
36. Attard, G., Reid, A. H., A'Hern, R., Parker, C., Oommen, N. B., Folkerd, E., Messiou, C., Molife, L. R., Maier, G., Thompson, E., Olmos, D., Sinha, R., Lee, G., Dowsett, M., Kaye, S. B., Dearnaley, D., Kheoh, T., Molina, A., and de Bono, J. S. (2009) Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 27, 3742-3748
37. Hall, P. F. (1991) Cytochrome P-450 C21scc: one enzyme with two actions: hydroxylase and lyase. J. Steroid Biochem. Mol. Biol. 40, 527-532
38. Vasaitis, T., Belosay, A., Schayowitz, A., Khandelwal, A., Chopra, P., Gediya, L. K., Guo, Z., Fang, H. B., Njar, V. C., and Brodie, A. M. (2008) Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}- hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole- 1-yl)androsta-5,16-diene in prostate cancer. Mol. Cancer Therap. 7, 2348-2357
39. Bruno, R., Gover, T., Burger, A., Brodie, A., and Njar, V. (2008) 17 alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgenindependent prostate cancer cells via induction of the endoplasmic reticulum stress response. Mol. Cancer Therap. 7, 2828-2836
40. Cheng, Y., and Prusoff, W. (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108
41. Deleted in proof
42. Kampa, M., Papakonstanti, E. A., Hatzoglou, A., Stathopoulos, E. N., Stournaras, C., and Castanas, E. (2002) The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors that increase PSA secretion and modify actin cytoskeleton. FASEB J. 16, 1429-1431
43. Veldscholte, J., Berrevoets, C. A., Ris-Stalpers, C., Kuiper, G. G., Jenster, G., Trapman, J., Brinkmann, A. O., and Mulder, E. J. (1992) The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. Steroid Biochem. Mol. Biol. 41, 665-669
44. Hara, T., Miyazaki, J., Araki, H., Yamaoka, M., Kanzaki, N., Kusaka, M., and Miyamoto, M. (2003) Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. 63, 149-153 (Pubitemid 36070433)
45. Reddy, G. P., Barrack, E. R., Dou, Q. P., Menon, M., Pelley, R., Sarkar, F. H., and Sheng, S. (2006) Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormonerefractory prostate cancer. J. Cell. Biochem. 98, 1408-1423 (Pubitemid 44141847)
46. Danila, D. C., Morris, M. J., de Bono, J. S., Ryan, C. J., Denmeade, S. R., Smith, M. R., Taplin, M. E., Bubley, G. J., Kheoh, T., Haqq, C., Molina, A., Anand, A., Koscuiszka, M., Larson, S. M., Schwartz, L. H., Fleisher, M., and Scher, H. I. (2010) Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol. 28, 1496-1501
47. Ikezoe, T., Yang, Y., Saito, T., Koeffler, H. P., and Taguchi, H. (2004) Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells. Cancer Sci. 95, 271-275
48. Pajonk, F., van Ophoven, A., and McBride, W.H. (2005) Hyperthermiainduced proteasome inhibition and loss of androgen receptor expression in human prostate cancer cells. Cancer Res. 65, 4836-4843 (Pubitemid 40740822)
49. Cinar, B., De Benedetti, A., and Freeman, M.R. (2005) Post-transcriptional regulation of the androgen receptor by Mammalian target of rapamycin. Cancer Res. 65, 2547-2553 (Pubitemid 40490049)
50. Mizokami, A., and Chang, C. (1994) Induction of translation by the 5′- untranslated region of human androgen receptor mRNA. J. Biol. Chem. 269, 25655-25659 (Pubitemid 24336260)
51. Shamji, A. F., Nghiem, P., and Schreiber, S. L. (2003) Integration of growth factor and nutrient signaling: implications for cancer biology. Mol. Cell 12, 271-280 (Pubitemid 37238914)
52. Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H., Chu, T. M., Mirand, E. A., and Murphy, G. P. (1983) LNCaP model of human prostatic carcinoma. Cancer Res. 43, 1809-1818 (Pubitemid 13122588)
53. Mukhopadhyay, N. K., Kim, J., Cinar, B., Ramachandran, A., Hager, M. H., DiVizio, D., Adam, R. M., Rubin, M. A., Raychaudhuri, P., DeBenedettì, A., and Freeman, M. R. (2009) Heterogeneous nuclear ribonucleoprotein K is a novel regulator of androgen receptor translation. Cancer Res. 69, 2210-2218
54. She, Q. B., Halilovic, E., Ye, Q., Zhen, W., Shirasawa, S., Sasazuki, T., Solit, D. B., and Rosen, N. (2010) 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 18, 39-51
55. Schayowitz, A., Sabnis, G., Njar, V. C., and Brodie, A. M. (2008) Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Mol. Cancer Ther. 7, 121-132
56. Holcik, M., Lefebvre, C., Yeh, C., Chow, T., and Korneluk, R. G (1999) A new internal-ribosome-entry-site motif potentiates XIAP-mediated cytoprotection. Nat. Cell Biol. 1, 190-192 (Pubitemid 129656025)
57. Seligson, D. B., Hongo, F., Huerta-Yepez, S., Mizutani, Y., Miki, T., Yu, H., Horvath, S., Chia, D., Goodglick, L., and Bonavida, B. (2007) Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence. Clin. Cancer Res. 15, 6056-6063 (Pubitemid 350075062)
58. Ryan, C. J., Smith, M. R., Fong, L, Rosenberg, J. E., Kantoff, P., Raynaud, F., Martins, V., Lee, G., Kheoh, T., Kim, J., Molina, A., and Small, E. J. (2010) Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin. Oncol. 28, 1481-1488
59. Reid, A. H., Attard, G., Danila, D. C., Oommen, N. B., Olmos, D., Fong, P. C., Molife, L. R., Hunt, J., Messiou, C., Parker, C., Dearnaley, D., Swennenhuis, J. F., Terstappen, L. W., Lee, G., Kheoh, T., Molina, A., Ryan, C. J., Small, E., Scher, H. I., and de Bono, J. S. (2010) Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol. 28, 1489-1495